Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism

Molecular Medicine Reports

Volumn 5, Issue 3, 2012, Pages 729-733

  Miyazaki, Masayuki ^a   Kato, Masaki ^a   Tanaka, Kosuke ^a   Tanaka, Masatake ^a   Kohjima, Motoyuki ^a   Nakamura, Kazuhiko ^a   Enjoji, Munechika ^b   Nakamuta, Makoto ^c   Kotoh, Kazuhiro ^a   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Body mass index; Cholesterol; Dipeptidyl peptidase 4; Fatty acids; Insulin resistance; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV; LACTATE DEHYDROGENASE; MESSENGER RNA; OLEIC ACID; PALMITIC ACID; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN RESISTANCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BODY MASS INDEX; CHOLESTEROL; DIPEPTIDYL PEPTIDASE 4; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; HEP G2 CELLS; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84863039515     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.707     Document Type: Article

References (24)

1. Browning JD and Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114: 147-152, 2004. (Pubitemid 39071617)
2. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 346: 1221-1231, 2002.
3. Zafrani ES: Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch 444: 3-12, 2004.
4. Mlinar B, Marc J, Janez A and Pfeifer M: Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 375: 20-35, 2007. (Pubitemid 44584240)
5. Neumiller JJ, Wood L and Campbell RK: Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 30: 463-484, 2010.
6. Ohnuma K, Munakata Y, Ishii T, et al: Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol 167: 6745-6755, 2001. (Pubitemid 33144164)
7. Buhling F, Kunz D, Reinhold D, et al: Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat Immun 13: 270-279, 1994. (Pubitemid 24326646)
8. Schmiedl A, Krainski J, Schwichtenhovel F, et al: Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins. Clin Exp Allergy 40: 1794-1808, 2010.
9. Hildebrandt M, Rose M, Ruter J, et al: Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol 36: 1067-1072, 2001. (Pubitemid 32801692)
10. Begriche K, Igoudjil A, Pessayre D, et al: Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6: 1-28, 2006.
11. Tilg H and Moschen AR: Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14: 222-231, 2008. (Pubitemid 351481853)
12. Okamoto Y, Tanaka S and Haga Y: Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model. Hepatol Res 23: 138-144, 2002. (Pubitemid 36113479)
13. Enjoji M, Machida K, Kohjima M, et al: NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids Health Dis 12: 9-29, 2010.
14. Enjoji M and Nakamuta M: Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? World J Gastroenterol 16: 800-803, 2010.
15. Higuchi N, Kato M, Shundo Y, et al: Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol Res 38: 1122-1129, 2008.
16. Firneisz G, Lakatos PL, Szalay F, et al: Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand J Gastroenterol 36: 877-880, 2001. (Pubitemid 32656564)
17. Andrieu T, Thibault V, Malet I, et al: Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol 27: 59-68, 2003. (Pubitemid 36513590)
18. Itou M, Kawaguchi T, Taniguchi E, et al: Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol 23: 244-251, 2008. (Pubitemid 351257677)
19. Lakatos PL, Firneisz G, Borcsiczky D, et al: Elevated serum dipeptidyl peptidase IV (CD26, EC 3.4.14.5) activity in experimental liver cirrhosis. Eur J Clin Invest 30: 793-797, 2000.
20. Firneisz G, Varga T, Lengyel G, et al: Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 18: e12226, 2010.
21. Balaban YH, Korkusuz P, Simsek H, et al: Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 6: 242-250, 2007.
22. Ryskjaer J, Deacon CF, Carr RD, et al: Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 155: 485-493, 2006. (Pubitemid 44463956)
23. McKillop AM, Duffy NA, Lindsay JR, et al: Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 79: 79-85, 2008.
24. Yang J, Campitelli J, Hu G, et al: Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 81: 272-279, 2007. (Pubitemid 47030570)